test

Solid Tumors

10
A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination with BMS-936558 (Anti-PD-1) in Subjects with Advanced or Metastatic Solid Tumors
Disease/Condition: Melanoma, skin
Principal Investigator: Mario Sznol
A Phase I Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Cervix Uteri | Colon | Esophagus | Kidney | Larynx | Liver | Lung | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs
Principal Investigator: Lajos Pusztai
A Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies
Disease/Condition: Bladder | Breast - Female | Colon | Esophagus | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Lung | Melanoma, skin | Multiple Myeloma | Non-Hodgkin's Lymphoma | Other Digestive Organ | Other Male Genital | Pancreas | Prostate | Rectum | Soft Tissue | Stomach | Thyroid
Principal Investigator: Roy Herbst
A Phase I/II Study of the Combination of BKM120 and Bevacizumab, Glioblastoma Multiforme
Disease/Condition: Brain and Nervous System
Principal Investigator: Kevin Becker
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects with Advanced Solid Tumors
Disease/Condition: Bladder | Breast - Female | Lip, Oral Cavity and Pharynx | Stomach
Principal Investigator: Lajos Pusztai
Phase Ib Trial of MPDL3280A with Bevacizumab or with Bevacizumab + FOLFOX in Patients with Solid Tumors
Disease/Condition: Colon | Lung | Rectum
Principal Investigator: Howard Hochster
V212 (inactivated varicella-zoster virus vaccine) in Adult Patients with Solid Tumor or Hematologic Malignancies
Principal Investigator: Debra Brandt